Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) are leading the fast-growing market for weight loss drugs, but they have had very different fortunes over the past year. Eli Lilly's shares have gained 41%, while Novo's have dropped 15%. Both could make significant progress in the next year, especially since they have important clinical candidates in Phase 3 studies. However, they could also face headwinds, including increased competition in the weight-loss space. With that said, should investors consider putting their hard-earned cash into Eli Lilly and Novo? Let's find out how much $10,000, invested equally in both stocks, could be worth by the end of 2027. Image source: Getty Images. Continue reading